---
title: "Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296384188.md"
description: "H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Cogent Biosciences with a $55 price target, citing its strong late-stage pipeline and solid cash position. Key catalysts include upcoming FDA decisions for bezuclastinib and IND submissions. The firm notes the company's runway into late 2028 reduces near-term financing risk. Piper Sandler also maintains a Buy rating with a $55 target."
datetime: "2026-08-19T16:45:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296384188.md)
  - [en](https://longbridge.com/en/news/296384188.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296384188.md)
generator: "portal-rs"
---

# Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Cogent Biosciences, with a price target of $55.00.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Robert Burns has given his Buy rating due to a combination of factors, including Cogent Biosciences’ strong late‑stage pipeline and solid financial position. He highlights the upcoming FDA decisions on bezuclastinib in GIST and non‑advanced systemic mastocytosis, along with additional IND submissions for other targeted oncology candidates, as key value‑creating catalysts over the next year.

Burns also underscores Cogent’s sizable cash balance and projected runway into late 2028, which supports ongoing development with limited near‑term financing risk. Using a DCF framework that applies high probabilities of approval across bezuclastinib’s lead indications, he arrives at an unchanged 12‑month price target of $55, while acknowledging typical biopharma risks such as clinical, regulatory, and commercialization uncertainties. 

In another report released on August 17, Piper Sandler also maintained a Buy rating on the stock with a $55.00 price target.

### Related Stocks

- [COGT.US](https://longbridge.com/en/quote/COGT.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)

## Related News & Research

- [HC Wainwright Brokers Decrease Earnings Estimates for COGT](https://longbridge.com/en/news/296613212.md)
- [Research Analysts Set Expectations for COGT Q1 Earnings](https://longbridge.com/en/news/296480559.md)
- [CIBC Sticks to Their Buy Rating for Thesis Gold Inc (TAU)](https://longbridge.com/en/news/296247637.md)
- [Goldman Sachs Reaffirms Their Buy Rating on H World Group (HTHT)](https://longbridge.com/en/news/296230638.md)
- [Regulatory Catalysts and Launch Readiness for Bezuclasitinib Underpin Sam Slutsky’s Buy Rating on Cogent Biosciences](https://longbridge.com/en/news/295460460.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**